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1. Introduction
The ability of embryonic stem cells to self renew and, at a given signal, give rise to the multi‐
faceted cell types normally observed in the body, is highly dependent on the complex inter‐
play between both intrinsic (inside the cell) and extrinsic (outside of the cell) factors. Despite
progress in analyzing the genome, proteome, and the transcriptome, challenges still exists to
find the most efficient and specific conditions in which human embryonic stem cells (hESC)
can maintain pluripotency and or/can be efficiently directed to differentiate towards a ho‐
mogenous cell type. In a stem cell niche, the integrity of the cell matrix and the manifold of
different cell-cell interactions and the ability of the cells to respond to a variety of cytokine
cues from both interstitial fluids and from extracellular matrices, are crucial factors in giving
the right signal signals to the cells internal machinery, in a space (spatio) and time (tempo‐
ral) manner during different developmental stages. One of these molecules is the glycan. A
glycan is a polysaccharide or oligosaccharide, that is attached to a glucoconjugate such as
glycoprotein, glycolipid, and proteoglycan. Cell surface glycoproteins are abundant and
constitute approximately 50% of all proteins in nature. For many years, the biological func‐
tion of glycosylation in stem cell behavior/homeostasis was overlooked and thought of as a
more or less redundant process with applications only limited to the identification and sort‐
ing of cells at different stages of pluripotency and during formation of induced pluripotent
stem cells (iPSC). Markers such as stage specific embryonic antigen (SSEA1 and -3/4) and the
tumor rejection antigens (TRA-1-60 and TRA-1-81) have been used to analyze the pluripo‐
tency and differentiation stages of embryonic stem cells and induced pluripotent stem cell
(iPSC).The research of how glycosylation can impact stem cells has long been hampered by
the structural complexities of glycosylation and the difficulties to identify and purify the en‐
zymes, glycosyltransferases, responsible for these processes. This problem is partly due to
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the fact that glycans are not encoded directly from the genome but rather depends on the
collaboration of a limited number of both glycosyltransferases and glycosidases, whose ex‐
pression are reliant upon both intracellular as well as extracellular changes. Furthermore,
glycosyltransferases are expressed differentially between many cell types and disease states
in a spatio- temporal manner during development. In this review, I will summarize research
on what is known for glycosyltransferases in stem cell pluripotency and differentiation. I
will specifically focus on one glycosyltransferase, N-acetylglucosamin β1,4- Galactosyltrans‐
ferase 1 (β4Gal-T1), a unique galactosyltrasferase implicated in a variety of cellular process‐
es such as cell-cell and cell-matrix adhesion, apoptosis, proliferation and differentiation, to
mention a few. I will discuss its regulation and potential mechanism(s) in cell-cell, cell-ma‐
trix and cytokine signaling pathways. Finally, in the last section, I will talk about some dis‐
eases related to galactosyltransferase deficiency. All in all, this chapter is intended to evoke
more interest in the field of stem cell glycobiology, both for the layman as well as for the
bench scientist. Ultimately, the goal of this review is to encourage future research to find al‐
ternative therapeutic modalities for glycoprotein related diseases, such as cancer, congenital
disease and even Alzheimer’s.
2. What is glycosyltransferases?
Glycosyltransferases (GTs; EC 2.4.x.y) constitute a large protein family of about 200-300 en‐
zymes that are involved in the biosynthesis of glycans. GTs are type II transmembrane pro‐
teins with large carboxy-terminal globular catalytic domains, that face the luminal side of
the Golgi complex, and a short cytoplasmic domain. The sequential action of GTs results in
the formation of both linear as well as highly branched glycan structures that are present in
both prokaryotes and eukaryotes. Mammalian GTs utilize a variety of uridine diphosphate
activated (UDP) sugars as donors: UDP-glucose, UDP-galactose, UDP-GlcNAc, UDP-Gal‐
NAc, UDP-xylose, UDP-glucuronic acid, GDP-mannose, GDP-fucose, and CMP-sialic acid.
Glycosyl transfer can occur on protein residues, usually to asparagine, to give N-linked gly‐
coproteins and on tyrosine, serine, or threonine to give O-linked glycoproteins [1]. The first
step in N-linked glycosylation occurs in the endoplamic reticulum (ER) in which a “high
mannose” oligosaccharide branch is added to an Asparagine (Asn) residue in the protein
backbone (N-linkage). Another type of glycan linkage is the O-linked glycosylation, which
occurs through serine/threonin residues in the protein back bone during transport within
the Golgie complex [2]. Other GTs are responsible for extensive branching of glycan struc‐
tures such as the galactosyltransferase family (GalTs) [3] which together with glycosidases
give rise to more “complex” type sugar chains (Figure 1). These processes creates oligosac‐
charide structures of enormous diversity and whose functions spans from cell adhesion, in‐
flammation, cancer metastasis, stem cell proliferation and development [4]. This exciting
area of biology has resulted in an intensive research to unveil the function of individual GTs
in during stem cell pluripotency and differentiation. Several studies have implicated a varie‐
ty of GTs in stem cell biology, some of which are presented below:
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Figure 1. General view of an O-linked (A), and a (B) “complex” N-linked cell surface glycoprotein. A lactosylceramide‐
glycolipid (LacCer) (C) is also shown, located at the upper leaflet of the plasma membrane (PM). Ser; Serine, Thr;Threo‐
nine, Asn;Asparagine Sial;Sialic acid, Gal;Galactose, Glc;Glucose,Man;Mannose, GlcNac; N-Acetylglucoseamine,
GalTNAc; N-Acetylglucoseamine, Fuc;Fucose
1. N-acetylglucosaminyl-1 phosphate transferase (GPT): The first steps in N-linked glycan
synthesis begins on both the cytosolic and luminal side of the endoplasmic reticulum
where nine mannosyl residues are sequentially added to a poly-isoprenoid lipid, doly‐
chylmonophosphate by the activity of N-acetylglucosaminyl-1 phosphate transferase
(GPT) and a number of mannosyltransferases. One inhibitor to GPT, tunicamycin (TM),
inhibits N-linked glycosylation and has been reported affect cell proliferation, neu-vas‐
cularization and cancer progression, due to induced cell death from ER stress [4].
2. βGalNAc-T3: The cell surface glycan epitope LacdiNac (GalNac-β4GlcNAc) has been
shown to be an important glycosylation modification of leukemia inhibitor factor recep‐
tor (LIFR) and its co-receptor, gp130.The addition of LacdiNac epitopes to LIFR was de‐
pendent on a specific transferase, β-3-N-acetyl-Galactosyl transferase 3 (βGalNac-T3).
This modification is crucial for the localization of LIF to lipid rafts/ calveolar compo‐
nents, such as caveolin-1, in order to enhance its activity. Mouse and human stem cells
(mESC, hESC) differ from each other in some aspects on how they respond to cytokines
necessary for pluripotency. hESCs seem to be at a later developmental stage than
mESCs, because of their independency of the LIF pathway for self renewal. Interesting‐
ly, the level of βGalNac-T3 was much lower in human versus mouse embryonic stem
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indicating that LacdNac play an important role for adopting stem cells from a primed
state (already programmed for germ line specification) to a more naïve state, e g fully
pluripotent cells[5]
3. Ext1 and Ext2: Heparan sulphate is a large sulphated oligosaccharide chain located on
proteoglycans impacting both the stability of pluripotency and differentiation into neu‐
ral stem cell lineage. Ext1 and Ext2 encodes two bifunctional endoplasmic reticulum-
resident type II transmembrane glycosyltransferase that are involved in the chain
elongation and modification of HS biosynthesis. HS on embryonic stem cells has been
shown to exhibit a lower amount of sulfated glycosaminoglycans relative to differenti‐
ated cells indicating that the ratio between nonsulphated versus sulphated HS is impor‐
tant in stem cell pluripotency [6-8]
4. O-GlcNac Transferase (OGT): O-GlcNAcylation is a O-β-glycosidic attachment of a sin‐
gle N-acetyl glucosamine to a serine or threonin residue in nucleoplasmic proteins.
Some of these proteins are represented by the transcription factors Oct4, Klf4, Sox and
Nanog, which are involved in the pluripotency network in stem cell self renewal and in
the core proteins responsible for the production of induced pluripotent stem cells
(iPSCs). Recently it was discovered that this specific O-linked modification of Oct4 and
Sox was crucial for their transcriptional activities. Two enzymes are responsible for O-
GlcNAcylation: O-GlcNac Transferase (OGT) adds the modification and O-glucNAcase
removes it [9].
3. β-1,4-Galactosyltransferases
β-1,4-Galactosyltransferases (β4GalTs) are type II membrane proteins of the glycosyltrans‐
ferase family that have the exclusive specificity to transfer an active UDP-galactose in a β1,4
linkage to acceptor sugars such as N-acetylglucosamine (GlcNAc), Glucose (Glc), Galactose
(Gal) and even Xylose (Xyl). Each β4-GalTs have a distinct function in the biosynthesis of
different glycoconjugates and disaccharide structures.The most common structure, the
Galβ1-β4GlcNAc, or N-Acetyllactosamine, exists as disaccharide repeats within linear or
branched poly-N-acetyllactoseamine chains, but also at the terminal ends of oligosaccharide
chains where they become sialyllated. These structures are formed by a combined action of
UDP-GlcNac:Mannosyl N-acetylglucosaminyltransferases and β-1,4-galactosyltransferases
(β4GalTs) [10]. The first galactosyltransferase, β4GalT-1, was cloned in 1986 due to its func‐
tion of transfer galactosyl residues to β-1,4-linked GlcNac found in glycoconjugates [11].
Targeted inactivation of mouse β4Gal-T1 gene, however, revealed that both tissue and se‐
rum glycoproteins still contained residual β4GalT-1 activity towards glycoprotein acceptors
[10]. To date there are currently seven members of the β4GalT gene family designated
β4Gal-T1-T7. Even though, β4Gal-T1 to -T6 shares various homologies (30-50%) to β4GalT-1
at the amino acid level, their substrate affinities and end products appear to be slightly dif‐
ferent, depending on nature of the branched oligosaccharide structure tissue expression and
the cellular milieu for the enzymes, e.g. lipid -rich environment [12, 13]. Both β4Gal-T1 and
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β4Gal-T2 preferentially transfer galactose to the GlcNacβ1-2Manα and the
GlcNAcβ1-4Man1-3 branch. β4Gal-T4 and β4Gal-T5 catalyzes the addition of galactose to
GlcNAcβ1-6Man and the GlcNAcβ1-4 Man, respectively (Figure 2). The β4Gal-T1, β4Gal-T2,
and β4Gal-T3 can also transfer galactose residues to tetra-antenna oligosaccharides. In addi‐
tion being involved in glycoconjugate synthesis, β4Gal-T2, -3, -4 and -6, are also important
catalysts for glycolipid biosynthesis. β4Gal-T2 and -3 prefers a glycolipid intermediate,
Lc3Cer, as a substrate and β4Gal-T4 uses GlcNac-6-sulphate, a common constituent of kera‐
tin sulphate, as a substrate [14]. β4Gal-T6 has been shown to have Lactosyl Ceramide syn‐
thase activity. Finally, β4Gal-T7, transfers a Galactose to an O-linked Xylose on a serine
residue to start the synthesis of the linker region between glycosaminoglycans (GAG) and
proteoglycans [15]. A general summary or the chromosomal location, tissue expression, gly‐
cosidic linkage and potential biological function of currently known β, 4-GalTs is summar‐
ized in Table 1.
Figure 2. An example of a tetra antenna structure in a complex-type N-glycan. The numbers indicate the glycosidic
linkages. The arrows and the boxed areas represent the bonds catalyzed by β1,4-galactosyltransferase (β4GaIT, blue
area) and βGlcNAc Transferases (βGlcNAcT, green area), respectively. Gal; Galactose, Man: Mannose, GlcNAc; N-Acetyl‐
glucosamin, R; glycoprotein back bone.
4. β-1,4-Galactosyltransferase 1 (β4Gal-T1 )
One member of the β4galactosyltransferase family, that has got increased attention in stem
cell biology, is the β4Gal-T1. β4Gal-T1 catalyze the transfer of galactose (Gal) from uridine
diphosphate-galactose (UDP-Gal) to terminal N-Acetylglucosamine (GlcNac) residues of oli‐
gosaccharide chains in a β1,4 linkage, to form N-acetyllactosamine. β4Gal-T1 and βal-T2 are
unique among the β4galactosyltransferases (β4GalTs) genes that they form a heterodimer
with alpha-lactalbumin and changes substrate specificity from GlcNac towards Glucose
(Glc) as a substrate, forming lactose, a very common protein in the mammary glands. Inter‐
estingly, β4Gal-T1 is constitutively expressed. However, apart from β4Gal-T1, β4Gal-T2 is
only expressed in fetal brain. β4GalT-2 is a key regulator of glycosylation of the proteins in‐
β1,4-Galactosyltransferases, Potential Modifiers of Stem Cell Pluripotency and Differentiation
http://dx.doi.org/10.5772/54376
349
volved in neuronal development [16] and is responsible for the synthesis of complex-type
N-linked oligosaccharides in many glycoproteins, as well as the carbohydrate moieties of
glycolipids. Like the β4Gal-T1 enzyme, its substrate specificity is affected by alpha-lactalbu‐
min but is not expressed in lactating mammary tissue Apart from the other βGalTs, βGal-T1
encodes two protein isoforms produced by differential translation initiation at the 5’ end of
the mRNA transcript: a long isoform, containing a 24 amino acid cytoplasmic domain, and a
short isoform with only an 11 amino acid domain [24]. Both isoforms are localized to trans-
Golgi network and are able to function as glycoprotein processing enzymes (Fig.3). Howev‐
er, a small fraction of the long isoform of βGaT-1, preferentially targets the cell surface of
various cells [25]. The specific signal sequence in β4GalTs that regulate the differential local‐
ization between cell surface and the Golgi complex, has been shown to consist of a short N-
terminal hydrophobic sequence in the cytoplasmic domain, adjacent to the plasma
membrane. This observation was further extended by the findings that the 13 amino acid se‐
quence in the cytoplasmic domain of long Gal-T1, could be phophorylated by p58 (CDK11),
a GalT1 associated and cell cycle related Serine/Threonin kinase and, hence, could act as a
retention signal for β4Gal-T1 in the Golgi complex [26, 27, 28, 38, 55] (Fig.3). Apart from be‐
ing involved in a variety of physiological activities, such as, for example mouse gamete in‐
teraction, neurite extension, epithelial mesenchymal transition and neural crest cell
migration [29], cell surface GalT1 is also responsible for late morula compaction during de‐
velopment [30]. For more than a decade ago, β4Gal-T1 was found to facilitate cell migration
on laminin 1, an important constituent of the extra cellular matrix (ECM) and during devel‐
opment [31, 32]. Furthermore, addition of β4Gal-T1 perturbants to F9 embryonic carcinoma
led to an arrest in cell growth and morphological changes of embryoid bodies (EB) during
differentiation [33]. Eckstein et. al., showed that cell surface β4Gal-T1 needed to associate
with intact actin cytoskeleton in order for its cell surface activity [34] Interestingly, the intra‐
cellular domain of long form of β4Gal-T1 has been shown to bind to an array of signal trans‐
duction molecules such as a trimeric G-proteins (Gi) [35], Src Suppressed C-kinase Substrate
(SSECKs) [36, 37], CDK11 (p58) [26, 38] and a novel ubiquitin conjugating enzyme [39]. The
β4Gal-T1 interaction with SSeCKS was detected using the two hybrid system with the ami‐
no terminal 13 amino acid long cytoplasmic domain of β4GalT-1 [37]. The β4Gal-T1 associa‐
tion with SSeCKS is interesting since both proteins show similar subcellular distributions
and share important cellular functions, such as cell proliferation, actin dynamics, and cell
migration during development [36, 40]. For example, ectopic expression of both cell surface
β4Gal-T1 and SSeCKS has been reported to induce a transient tyrosine phosphorylation of
focal adhesion kinase (FAK) and rearrangement of filamentous actin [41]. Furthermore,
SSeCKs also control the G1 to S phase progression through regulation of cyclin D1 expres‐
sion and localization. Since SSeCKS is a scaffolding molecule that can binds to several sig‐
naling proteins, such as PKC, Rho family members, and FAK, to mention a few, it is possible
that most effects attributed to cell surface GalT1 in stem cell growh and differentiation may
be mediated through SSeCKS. However it is unclear if cell surface β4GalT-1 performs in a
similar manner as a lectin for its biological function [42, 105] or whether it utilizes its enzy‐
matic activity to modify and release its galactosylated product [31].
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(β4GalTs)
(Chrom. #)
Expression Glycosidic linkage and
Acceptor substrates
Function in stem cell, cancer
and/or development
References
β4Gal-T1
(9p13)
Heart, liver, lung, testis,
ovary, placenta, fetal brain
Galβ1-4GlcNac-R Morula compaction, cell
growth, laminin dependent
migration
[17], [18]
β4Gal-T2
(1p32-33)
Restricted in brain, testis Galβ1-4GlcNac-R
Glycolipid
Neuronal development,
spermatogenic
differentiation
[16], [18]
β4Gal-T3
(1q23)
Constitutively expressed,
high in fetal brain.
Galβ1-4GlcNac-R
Glycolipid
N/A [14]
β4Gal-T4
(3q13.3)
Testis, ovary, placenta,
pancreas
Galβ1-4GlcNac-R
GlcNac-6-sulphate LacCer
Testicular development,
tumor metastasis, keratin
sulfate synthesis.
[19], [14], [20, 21]
β4Gal-T5
(11)
heart, lung, liver, kidney,
testis, Restricted in brain
Galβ1-4GlcNac-R
LacCer
Self renewal of glioma cells,
astrocytoma, extraembryonic
development
[18], [22]
β4Gal-T6
(18q)
Restricted to adult brain Galβ1-4GlcNac-R
LacCer
Extra embryonic
development
[18, 19]
β4Gal-T7
(5q35.1-35.3)
Heart, Brain, Placenta,
Liver, kidney, pancreas
GlcAβ1-3Galβ1-3Galβ1-4
Xylβ1-R
Glycosaminoglycan (GAG)
biosynthesis
[15, 23]
Table 1. Table depicting the chromosomal region, the glycosidic linkage, substrate, and the function for the
β4Galactosyltransferase family, related to stem cells and development.
5. β4GalTs in cancer
Glycosylation of cell surface glycoproteins and glycolipids changes dramatically upon the
malignant transformation of cells [43]. β4GalTs have been reported to be increased in a fair
amount of cancer. However, is not currently known if the elevated expression of β4GalTs
contributes to the induction of cancer/malignancy, by affecting the cell surface landscape of
glycans, or is an indirect effect of cancer progression or metasisis. β4Gal-T1 has been detect‐
ed in highly metastatic lung cancer by transcription factor E1AF activation of the β4Gal-T1
promoter [17, 51]. Furthermore, siRNA interference of surface β4Gal-T1 function, inhibited
cell adhesion on laminin, the invasive potential in vitro,and tyrosine phosphorylation of fo‐
cal adhesion kinase [17]. The relative level of β4Gal-T1 has been reported to be important in
melanoma invasiveness. For example, increasing cell surface β4Gal-T1 expression in cells of
low metastatic potential promoted their invasive potential [44]. Other β4GalTs such as
β4Gal-T5, function as an important growth regulator in glioma cells using both the E1AF
and Sp1 transcription factors for its metastatic potential [17, 45]. Furthermore, clinically over
expressed β4Gal-T4 and β4Gal-T6 have been shown to increase E2F1 and cyclin D3 tran‐
scription in colorectal cancer, respectively [18, 19]. Moreover, β4Gal-T1, -T2 and -T5 levels
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are higher in astrocytoma [18]. The expression of the β4Gal-T5 gene has also been shown to
be regulated by transcription factors Sp1 and Ets-1 in cancer cells. Both these transcription
factors regulate the gene expression levels of not only glycosyltransferases, but also key
molecules involved in tumor growth, invasion and metastisis. Finally, small molecules that
increase expression of GalTs could have beneficial effects during treatment of various cancer
forms [45].
Figure 3. The long isomer of β1,4Galactosyltransferase 1 (β4GalT-1). β4GalT-1 catalyzes the transfer of UDP-galactose
(red circle) to a terminal N-Acetylglycosamine (GlcNAc) residue in a newly synthesized glycoprotein in the golgie lu‐
men. The cytosolic domain of the long β4Gal-T1 consists of 11 amino acids (a.a) together with a 13 a.a extension (24
a.a in total). Phosphorylation of Serine 11 (S11) and/or Theonine 18 (T18) in the cytoplasmic domain negatively regu‐
late the localization and function GalT-1 as a cell surface receptor. The figure is not in scale.
6. β4Gal-T1 in cell cycle
The observation that some, or maybe all, of the β4GalTs have relevancy in cancer progres‐
sion and/or metastasis, has highlighted the idea that stem cell pluripotency and differentia‐
tion may also depend on N-glycan structures [46]. One decisive factor in pluripotency and
stem cell differentiation is the speed by which cells goes through the G1 phase in the cell
cycle [47]. The cell cycle in pluripotent stem cells is remarkable for the shortness of the G1
phase, permitting rapid proliferation and reducing the duration of differentiation signal sen‐
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sitivity associated with G1 phase. Changes in the length of G1 phase are understood to ac‐
company the differentiation of human embryonic stem cells (hESCs), but the timing and
extent of such changes are poorly defined. Terminally differentiated cells usually have a lon‐
ger G1 phase than those of stem cell and progenitor cells. Understanding the early steps
governing the differentiation of hESCs will facilitate better control over differentiation for
regenerative medicine and drug discovery applications. To avoid that cells with genetic
aberrations are expanded in the population, stem cells have adapted to their harsh environ‐
ment by shutting off specific checkpoints normally activated in somatic cells. This will result
in cell death as a default pathway for stem cells exhibiting chromosomal deveations, with‐
out slowing down proliferation of otherwise healthy cells. Since the upstream promoter re‐
gion of the 4.1 kb β-GalT1 transcript is mainly occupied by the Sp1 transcriptional factor,
GalT1 was long believed to be another “house keeping” gene. However, several laboratories
have shown that β4GalT-1 is regulated during cell cycle [28, 48, 49]. Interestingly, experi‐
ments in F9 embryonic carcinoma cells and in 3T3 cells have indicated that the cell surface
bound and the Golgi related forms of β4GalT-1 are regulated differently, in which the long
form is induced much earlier than the short and Golgie bound form. β4Gal-T1 showed the
highest activity during G1-S phase and during interphase of the cell cycle [50]. There are
many transcription factors important during the G1-S transition. The E2F family members of
transcription factors serve as key regulators of the cell cycle progression by inducing activa‐
tors of S-phase related genes. Normally, during the onset of G1/S transition in cell cycle, the
cyclic dependent kinases (CDKs) phosphorylate the retina blastoma (Rb) protein, resulting
in a conformational change in Rb and subsequent release of active E2F from the Rb-E2F
complex. This event results in transcription of G1-phase activating proteins such as e.g Cy‐
clin D3. Interestingly, E2F1, one of the best characterized members of this family, also binds
to a promoter element in β4Gal-T1 transcript and positively regulates its activity. Moreover,
cells subjected to a short hairpin RNA (shRNA) to β4Gal-T1 became less responsive for E2F1
activation [51].The effect of E2F1 on the expression of the other family members of β4GalTs,
however, (β4Gal-T1, -T7) has not been exclusively determined. Another cell cycle related
protein that has been found to regulate β4GalT1 expression is the p16 protein. This protein
is a product of a tumor suppressor gene called CDKN2A that inhibits the cyclin-dependent
kinases (CDK)-4 and 6 which are responsible for the G1 checkpoint in cell cycle. Transfec‐
tion of A549 human lung cancer with p16 led to down regulation of βGalT1 activity [53].
Thus, inactivation of either p16 or pRb function allows the cells to enter the S-phase only
after a brief pause at the G1 checkpoint, leading to accelerated cell proliferation. Similar re‐
sults for GalT1 expression was obtained in hepatocarcinoma SMMC-7721 cells after blocking
endogenous activity of TGFβ, a known regulator of the G1 to S-phase transition of cell cycle,
by arresting cells in G1 phase [54]. Over expressing β4Gal-T1 has also been shown to exas‐
perate cyclohexamid induced apoptosis of [45]. This process is partly dependent on the ac‐
tivity of the CDK11(p58), a CDK11 family Ser/Thr kinase, a G2/M specific protein that
contributes to regulation of cell cycle [55]. Recently GalT1 has been shown to interact with
CDK11(p58) [26, 38] where it has an important function during cell cycle in stem cells pro‐
gression [28, 56]. Furhtermore, β4Gal-T1 contributes to HBx-induced cell cycle progression
In hepatoma cells [57]. All these findings have led to the conclusion that β4Gal-T1 may be
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directly or indirectly connected to cell cycle progression and could be a potential reason for
the growth impeded phenotype observed earlier in knock out β4Gal-T1 mice [52]
Figure 4. Biosynthesis of a core 2 O-glycan with Lewis X, (LeX,SSEA-1), Sialyl-Lewis (SLex) or 6-sulpho Sialyl (6-Sulpho-
Lex synthesized at the terminus of poly-N-Acetyllactosamine chains. The action of β4Ga|Ts and β3GnT are indicated
with arrows. Sia|;Sia|ic acid, Gal;Ga|act0se, G|c;G|uc0se, Man;Mann0se, G|cNac; N-Acetylglucoseamine, Ga|TNAc; N-
Acetylgalactoseamine, β4Ga|act0syltransferases; β4GalT, β1,3-N- Acetylglucosaminyltransferase; β3GnT
7. β4GalTs involvement in Lewis X, glycosphingolipids and
embryoglycans
Lewis X: As mentioned in the beginning of this chapter, β4GalTs are Important for the syn‐
thesis of linear or branched poly-N-acetyllactoseamines chains. They are attached to N-gly‐
can, O-Glycans or glycolipids and are synthesized by the repeating and alternate action of
N-acetylglucosaminyltransferases (β3GnT or β4GnT) and β4Gal-T1 [58]. These structures of‐
ten carry various functional epitopes important in stem cell homeostasis and inflammation
[59]. One of these antigen is called the Lewis X antigen (Lex) and constitutes the core struc‐
ture from which other antigens are synthesized. Lex epitope consists of a trisaccharide,
Galβ1-4(Fucα1-3) GlcNAcβ1 which is produced by the action of β4Gal-T1 and α-1,3-Fuco‐
syltransferase (FUT). Other examples of epitopes formed from this core, are the Sialyl-Lewis
(SLex ) and 6-sulpho Sialyl (6-Sulpho-Lex) epitopes (Figure 3), in which the latter involve the
activity of β4Gal-T4 (Table 1). These epitopes are implicated in biospecific interactions with
selectins and other glycan-binding proteins during inflammatory processes [59] as well as in
important regulatory functions during development [60]. Also, Lex structures has been im‐
plicated in specific differentiation, such as myocardial differentiation from embryonic stem
cells [60, 61].
Glycosphingolipids: Glycosphingolipids, or sometimes called glycolipids (GLS) have been
found in the upper leaflet of the plasma membrane in both lower and higher eukaryotic
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sources. Several members of β4GalT family seem to be important enzymes in the synthesis
of GSL [62]. The basic structure for GLS is a monosaccharide, usually glucose, attached di‐
rectly to a ceramide molecule, mediated through the action of ceramide glucosyltransferase
(Ugcg), resulting in a glycosylceramide (glucocerebroside;GlcCer) (Figure 5). βGalT-2 then
transfer a UDP-Galactose to the GlcCer moiety, forming Lactosylceramide (LacCer) [62]
(Figure 5). A variety of structural subclasses of GLS may then be synthesized from LacCer
by the addition of other mono and disaccharides, resulting in the synthesis of structural sub‐
classes of GLS such as ganglio-, lacto/neolacto-, globo,- -isoglo, and ganglioseries-series [63].
Many of these structures are important for various biological functions, such as for example
cell growth, myocardial differentiation cell migration and during development of the nerv‐
ous system[60, 61, 64]. When the Lex epitope is attached to a lactosylceramid it is identical to
stage specific antigen (SSEA-1). This antigen is highly regulated during embryogenesis, ex‐
pressed at the morula stage in embryos and is considered to function as a cell-cell interac‐
tion ligand in the compaction process [65].
Figure 5. Core 2 structure of the glycoplipid, Lactosylceramide (LacCer) synthesized by UDP-glucose ceramide glucosyl
transferase (Ugcg) and by β1,4Ga|act0sy|transferases (β4Ga|Ts) forming the β1,4-glycosidic linkage to ceramide.
Embryoglycans: Most developmentally regulated epitopes identified on embryonal carcino‐
ma cells and murine preimplantation embryos are associated with a glycoprotein-bound
and large glycans, called embryoglycans. Embryoglycans consists of linear of branched
poly-N-acetyllactoseamines with high molecular weight that carries a number of different
developmentally regulated carbohydrate epitopes, such as e. g. Lex, described above (Figure
6). Apart from the mouse, where SSEA-1 is abundant from the 8-cell morula stage, SSEA-1
in human is not expressed until the germ cell line and in neural stem cells. Interestingly,
β4Gal-T1 is expressed during the morula stage and has been shown to affect the compaction
process [30]. Furthermore, human ES cells express SSEA-3 and -4 SSEA-1. SSEA-1 is also ex‐
pressed in undifferentiated F9 teratocarcinoma cells. After induction of differentiation the
expression of SSEA-1 decreases. This is caused by the upregulation of alpha-1,3-galactosyl‐
transferase that is responsible for masking of the Lex structure [66, 67]. The stage specific
β1,4-Galactosyltransferases, Potential Modifiers of Stem Cell Pluripotency and Differentiation
http://dx.doi.org/10.5772/54376
355
embryonic antigens 3 and 4, (SSEA-3,-4) are from the globo-series of glycosphingolipids
(GL-5 and GL-7) and have not been found on linear poly-N-lactosamines [68].
Glycoseaminoglycans (GAG): GAGs are long unbranched polysaccharides containing a re‐
peating disaccharide unit. The disaccharide units contain either one of two modified sugars,
N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), and a uronic acid such
as glucuronate or iduronate, forming heparin sulphate and hondroitin sulphate, respectively
[69]. GAGs are highly negatively charged molecules, and are located primarily on the sur‐
face of cells or in the extracellular matrix (ECM). GAGs are normally attached to soluble or
membranes bound core proteins to form proteoglycans which carries various carbohydrate
markers expressed on early embryonic cells [60]. In the few past years it has become clear
that many growth factor such as EGF and FGF has been shown to bind specific pentasac‐
charides within GAGs efficiently affect signaling during development [70]. The integrity of
proteoglycans is important. One of the β4galactosyltransferase, β4Gal-T4, is one has recently
been shown to be involved in the biosynthesis of keratin sulphate (KS), in which TRA-1-60
and TRA-1-80 epitopes are found, [14]. Furthermore, β4GalT-7 is involved in the synthesis
of the GAG linkage region to proteoglycans, by catalyzing the transfer UDP-Gal to an O-
linked Xylose/Ser residue in the sequence, GlcAcβ1-3Galβ1-3Galβ1-4Xylβ1-O-ser [23].
8. βGalTs and ESC signaling pathways
A number of reports have suggested β4GalTs to be direct or indirect mediators and regula‐
tors of cytokine signaling during stem cell and/or cancer development. As discusses below,
many signal transduction pathways, such as EGF, FGF, Wnt and the Notch pathway, that
utilize Lex-containing carbohydrates are potential targets for aberrations in β4GalTs activi‐
ties:
8.1. Epidermal Growth Factor (EGF)
EGF is involved in the regulation of cell  proliferation and exerts its  effects in the target
cells  by  binding to  the  plasma membrane located EGF receptor.  The  EGF receptor  is  a
transmembrane protein tyrosine kinase. Binding of EGF to the receptor causes activation
of  receptor  autophosphorylation,  which  is  essential  for  the  interaction  of  the  receptor
with  its  cytosolic  substrates.  In  mouse  embryonic  stem  cells  (mESC),  EGF  has  been
shown to stimulate proliferation of mouse ES cells via PLC/PKC, Ca2+influx and p44/42
MAPK  signal  pathway  through  EGF  tyrosine  kinase  phosphorylation  [71].  Altering  the
core components of N-linked glycans will change the EGF binding, the transport and the
receptor  endocytosis  meanwhile  substitution  of  the  outer  chain  or  terminal  glucosides
have been shown to affect the phosphorylation state and the dimerization of the receptor
[72,  73].  Cell  surface βGalT1 has been suggested to associate with and disrupt autopho‐
phorylation of EGF receptor Hinton et.  al,  showed that when a dominant negative form
of  long β4GalT-1  was over  expressed in  F9  embryonic  carcinoma cells,  the  endogenous
and active cell surface GalT-1 is displaced from its association to actin cytoskeleton. This
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inhibition  of  cell  surface  β4GalT-1  resulted  in  increased  tyrosine  phophorylation  of  the
EGF receptor and attenuated cell proliferation, while the shorter form of βGal-T1 did not
have any effect [48]. These results implies that cell surface β4Gal-T1 has an inhibitory ef‐
fect on EGF activity. Later, several groups substantiated this observation by showing that
knock-down of β4GalT1 activity in SMMC7721 hepatocarcinoma cells,  elevated the auto‐
phosporylation of EGFR. Reversibly, the level of tyrosine phosphorylation was attenuated
if cell surface βGal-T1 was over expressed [74]. Interestingly, EGF treatment of HeLa cells
has been shown to increase the β4Gal-T1 mRNA level,  suggesting that β4GalT1 also act
in  a  negative  feedback  loop on  EGF activity  [17].  In  another  elegant  experiment,  using
mutant  Chinese  hamster  ovary  cells  (CHO),  where  the  levels  of  six  beta  β4Galactosyl‐
transferases  (βGalT1-6)  were  reduced,  the  protein  level  of  active  and  surface-located
EGFR  was  greatly  attenuated  without  affecting  the  transcriptional  level  and  activity  of
EGF receptor [75].  β4Gal-T1 has also been shown to positively affect EGFR activity. Iso‐
prenaline,  a  β-adrenergic  receptor  has  a  dramatic  growth  stimulating  activation  on  the
salivary  glands  of  rat  and  mice,  eventually  leading  to  hyperplastic  and  hypertrophic
gland enlargement. This effect has been suggested to be mediated in part by cell surface
β4Gal-T1  by  mimicking  EGF  receptor  mediated  receptor  ligand  binding  and  activation
[76].  In any case,  the specific  β4GalT1 binding site on the EGF receptor has not,  as yet,
been investigated but  it  is  possible  that  the  recently  discovered extracellular  location of
O-linked GlcNac moieties on the EGF receptor,  could act as a recognition signal,  as has
been  observed  for  other  membrane  anchored  extracellular  proteins,  such  as  Notch  and
Dumpy receptor [77, 78]. In this scenario, β4GalT1 could act as a lectin like molecule, us‐
ing its substrate, GlcNAc [79, 80].There are also possibilities for other, more indirect and
β4Gal-T1 dependent effects on EGF receptor function, such as the ganglioside GM3. The
synthesis of this glycolipid is dependent on β4Gal-T2 activity, and has been shown to in‐
hibit  ligand-induced  tyrosine  phophorylation  of  EGF  receptor  through  its  sialyllactose
carbohydrate moiety by interacting with the GlcNAc termini [72, 81].
8.2. FGF-2
Fibroblast growth factor (FGF) functions as a natural inducer of mesoderm, regulator of cell
differentiation and autocrine modulator of cell growth and transformation of various cell
types. FGF is activated by ligand-receptor interaction that results in tyrosine phosphoryla‐
tion of the intracellular domain of the FGF receptor [82]. FGF-2 is often used as a key player
in regulating self renewal and proliferation of human embryonic stem cells. Recently FGF-2
has been shown to regulate the transition from one pluripotent state to another. It has been
speculated that human embryonic stem cells, due to their precautious ability to differentiate
in culture, are identical to a later or “primed” developmental stage of mouse embryonic
stem cells, EpiESC. LIF signaling is dispensable for this state, but instead relies on FGF sig‐
naling. Inhibition of FGF signaling with inhibitors in the presence of human LIF can “res‐
cue” human embryonic stem cells from a primed state to a more naïve state, e g full
pluripotency [83].This difference is still unclear but there are indication that extracellular
proteoglycans, such as heparin sulphate (HSPG) acts as key co-activators of FGF receptors.
Furthermore, during development, oligosaccharides from embryoglycans are often shed in‐
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to the extra cellular environment where they can influence cytokine and mitogen signaling.
Lewis x epitopes on embryoglycans acts as a recognition molecule for FGF2 and plays an
active role in the formation of FGF ligand receptor complexes. Free and soluble sulphated
Lewis X was most prominent to activate the FGF-2 mitogenic acitivity [84, 85]. Also exoge‐
nous and free glycolipids in the form of gangliosides, can interact with the FGF-2. Ganglio‐
sides are derivatives of LacCer with a neuraminic acid (NeuAc) attached to the core, and
seem to have dual roles in affecting both EGF and FGF proliferative action; soluble ganglio‐
sides and sulphated heparin act in a negative manner meanwhile membrane bound ganglio‐
sides increase the receptor activity. It seems clear that the close interplay between Lex
epitopes, adhesion molecules and cytokines has an important impact on the efficiency by
which ligands are presented, and ultimately results in receptor oligomerization of the recep‐
tors and signalling [70]. It is therefore possible that β4GalTs could mediate some aspect of
FGF receptor signalling, as described below.
8.3. Wnt pathway
The Wnt family of growth/differentiation factors has important developmental roles in em‐
bryonic stem cells. They act through the complex of Frizzled receptor and LPR co-receptor
with effect on β-catenin transcriptional activity [86]. Similarly to EGF, the activity of Wnt al‐
so depends on association with HSPG for activity. HSPG is a rich source for developmental‐
ly regulated Lex epitopes. Furthermore, Wnt-1 has been shown to interact directly with Lex
epitopes [87]. These observations suggests that surface bound and secreted Lex have a regu‐
latory function in stabilizing the stem cell niche, where they binds to and present appropri‐
ate factors, important for cell proliferation and self renewal.
8.4. Notch pathway
In a stem cell niche, stem cells and a variety of progenitor cells have to receive both temporal
and spatial signals in order to differentiate or stay pluripotent. Also, during development
and differentiation, cells have to decipher their precise localization in the dorso-ventral
plane in order to form distinct and proper boundaries with other cell types in the tissue.
These processes are governed by the Notch/ Delta system [88]. Notch is an essential devel‐
opmental glycoprotein that plays key roles in both growth control and cell fate decisions. It
is a transmembrane glycoprotein with a large extracellular domain made up of 29-36 EGF
repeats, which can contain both N-linked and O-linked EGF repeats [90]. When Notch re‐
ceptor is activated by a ligand on adjacent cells it is proteolytically cleaved, disposing the
extracellular domain, followed by a second cleavage resulting in the released of the intracel‐
lular domain into the cytosol where it translocates to the nucleus and activates the transcrip‐
tion of numerous developmental genes. There are two ligands to Notch receptor, Delta and
Jagged. Even though Notch receptor is ubiquitously expressed, Delta and Jagged are not
usually located in the same cells but rather in different parts of the tissue during develop‐
ment where they exert their effect dependent on cell type and/or the environment. To avoid
ubiquitous activation, Notch undergoes a post translational modification in which Fucose is
first attached to certain EGF repeats on the extracellular domain of the receptor by O-Fuco‐
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syltransferase (O-FucT1). An N-acetyl glucosamine (GlcNac) and a Galactose (Gal) residue
are then sequentially added to the fucosyl residue by the action of Fringe, a O-fucose β1,3-
N-Acetyl glucosaminyl transferase and β4Gal-T1, respectively. The addition of Gal is neces‐
sary for the enhancement of Delta dependent signaling but not sufficient for the inhibition of
Jagged induced Notch activation [89]. Recently, another layer of regulation of Delta induced
Notch signaling was discovered in which the two Fringe genes, Lunatic Fringe (LFNG) and
Manic Fringe (MFNG), seem to exhibit differential activity toward Delta dependent Notch
activation. Gal was required for enhancement of Notch activation through LFNG and inhib‐
ited the enhancement of Delta induced signaling [90, 91]. Apart from O-linked Fucosylation,
an O-linked GlcNAc modification of Notch EGF repeats was recently discovered [77]. Al‐
though the O-GlcNac modification is known to regulate a wide range of cellular processes,
the list of known modified proteins has previously been limited to intracellular proteins in
animals. Thus, this novel finding predicts a distinct glycosylation process associated with a
novel regulatory mechanism for Notch receptor activity that may include a variety of
βGalTs [77]. Furthermore, continuous hypoxic culturing conditions have been shown to acti‐
vate Notch signaling to allow long-term propagation of human embryonic stem cells with‐
out spontaneous differentiation. Stem cells isolated and cultured under low oxygen tension
(hypoxia) condition have been shown to maintain a stable pluripotency potential because of
Notch activation [92]. Recently, it was also shown that β4GalT1 derived Lewis X epitopes on
N-linked glycans was necessary for Notch activity and in the propagation of neural stem
cells (NSC) [93].
9. β4GalTs deficiency in fish
It has been a challenge to get a consensus of the mechanisms by which complex carbohy‐
drates control aspects of mammalian development and early differentiation. Some of the
information  has  been  available  from  knock-down  experiment  of  individual  galactosyl‐
transferases.  However,  since  many carbohydrate  functions  during early  development  in
mammals are confined to “ in utero”, further analysis of the physiological effects of galac‐
tosyltransferases has not been possible. An attractive model using a more efficient “high-
throughput “ a assay system, is  the zebrafish system. β4Gal-T1:  The zebrafish β4Gal-T1
has the highest sequence homology to β4Gal-T1 among the human β4GalT family. β4Gal-
T1  morpholino  treated  embryos  had  a  truncated  anterior-posterior  axis  phenotype  that
was a result of a defect in convergent extension [94]. Convergent extension is a develop‐
mental process that relies on coordinated cell migration to elongate and narrow a field of
cells. Laminin is an extracellular substrate for cell surface β4Gal-T1 and constitutes one of
the major components of the basement membrane upon which cell  adhesion and migra‐
tion  occur  during  development  [29].  Interestingly,  in  the  mopholino  treated  embryos,
laminin  was  hypo-galactosylated  and  hence  could  explain  the  decreased  in  ectodermal
cell migration of [94]. β4Gal-T2: Tonoyama, et al. showed that β4Gal-T2 was indispensa‐
ble  for  mediolateral  cell  intercalation and thus  extension movement  during gastrulation
[95]. The specific substrates for β4Gal-T2 activity in glycoproteins responsible for these ef‐
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fects are currently not known but has been speculated to be related with N-glycosylated
FGF receptor signaling. FGF signaling pathway is dependent on its N-glycans in the in‐
teraction  with  heparin  co-receptor,  regulating  the  efficiency  of  signaling  [96].  β4Gal-T5:
Transforming Growth factor (TGFβ) and bone morphogenic protein (BMP) are polypep‐
tide  members  of  the  transforming  growth  factor  beta  (TGF)  super  family  of  cytokines.
They are both secreted protein that performs many cellular functions, including the con‐
trol  of  cell  growth,  cell  proliferation,  cell  differentiation  and  apoptosis.  In  this  context,
knock-down of  β4Gal-T5  using  morpholino-injected  zebrafish  resulted  in  embryos  with
an elongated dorso-ventral axis and a defective tail bud [97]. This effect was suggested to
be mediated through a decreased BMP-2 (a TGFβ family member) binding to proteogly‐
can due to defective glycosylation, and subsequent attenuation of SMAD signaling.
10. β4GalTs deficiency in mouse and human
Many diseases  such as  disorders  of  blood clotting,  congenital  disorder  of  glycosylation,
diseases of blood vessels, cancer, angiogenesis essential for breast and other solid tumor
progression and metastasis,  are all  associated with a dysfunctional  N-glycan expression.
The  expression  of  many  galactosyltransferases  is  under  control  of  cytokines  and  could
therefore  become  altered  in  various  disease  states.  In  order  to  find  physiological  func‐
tions for  each galactosyl  transferases,  researchers have used both mouse and rat  knock-
out models. β4Ga-T1:  β4Ga-T1 was the first galactosyltransferase that indicated potential
relevance  in  physiology.  About  50% of  β4Gal-T1,  knock-out  mice  died  prematurely  be‐
cause of pituitary deficiency [10].The surviving animals showed growth retardation,  ele‐
vated  proliferation  of  skin  epidermis,  and  delayed  wound  healing  due  to  attenuated
leukocyte  recruitment  and  infiltration  [59].  Recently,  some  diseases  in  humans  due  to
aberrations  in  β4Gal-T1  have  emerged.  For  example,  congenital  disorders  of  glycosyla‐
tion  (CDGs)  comprise  a  group of  inherited  disorders  associated  with  psychomotor  and
mental  disorders.  One  of  these  groups,  CDGII,  comprises  all  defects  in  trimming  and
elongation of  N-linked oligosaccharides.  CDGIId fall  into a  group in which β4Gal-T1 is
mutated in its catalytic domain. This resulted in an aberrant translation product that was
15 kDa shorter  than normal.  Since β4GalT-1 has been shown to be is  important  during
the early development of the brain, the phenotype from this mutation is mental retarda‐
tion [98]. β4Gal-T5: Furthermore, knock-out β4Gal-T5 in mouse resulted in growth retar‐
dation and early lethality of embryos due to hematopoietic and/or placental defects [99].
Also the expression of β4Gal-T5 strongly increased during embryonic stem (ES) cell  dif‐
ferentiation  [22].  Both  β4Gal-T5  and  β4Gal-T6  are  lactosylceramid  synthases.  However,
β4Gal-T5 is more restricted to the early embryogenisis than β4Gal-T6, which is more lim‐
ited to adult  brain.  β4GalT-5 deficient animals showed abnormal extra embryonic struc‐
tures  that  led  to  embryonic  lethal  phenotype  at  day  E10.5.  β4Gal-T7:  A  rare  genetic
mutation of β4Gal-T7,  believed to be the consequence of two missense mutations in the
active  domain  resulted  defective  GAG  chain  formation  [15]  gives  rise  to  Ehlers-Danlos
disease.  This  is  a  disorder  in  which  patients  exhibit  phenotypes  such  as  aged  appear‐
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ance, developmental delay, dwarfism, craniofacial disproportion, delayed wound healing,
loose skin, and general ostopenia [15, 100].
11. Potential treatments
The involvement of β4GalTs in cancer, inflammation and during development / stem cell
homeostasis  has  encouraged  research  to  come  up  with  new  modalities  that  can  either
boost  or  inhibit  the expression/activity of  endogenous glycosyltransferases.  I  will  briefly
discuss potential therapeutic models for treatment that will inhibit or activate specific gal‐
actosyltransferases.
11.1. Protein ubiquitination
A potential regulator of a galactosyltransferase, GTAP, was discovered 2008 in a two hybrid
screen of a mouse embryonic library, using the cytoplasmic domain of cell surface Gal-T1 as
bait. Ectopically expressed GTAP down regulated the expression of cell surface bound
GalT-1 and negatively affected both laminin dependent stem cell migration and embryonic
body formation during differentiation. GTAP is an ubiqutin conjugating enzyme that is ex‐
pressed during early development of the inner cell mass and in embryonic stem cells but al‐
so in highly proliferative tissues, such as, such as kidney, lung and testis. This effect was not
due to a proteasome dependent degradation of βGal-T1 but an increase of ubiquitin depend‐
ent lysosomal activity. So far this is the only report on ubiquitin related regulation of a cell
surface galactosyltranferase and may be important for the development of more effective
and specific inhibitors of various glycosyltransferases in glycan related diseases. The only
known ubiquitin/proteaseome regulated system of glycans so far, is the endoplasmic reticu‐
lum assisted degradation (ERAD).This system helps cells to avoid stress and cell death by
degradation of missfolded proteins in the ER [101]
11.2. Analogues to GalT donor and acceptor
A limited number of GalT-1 inhibitors have been described. Most of them have been ana‐
logues of either the donor substrate (e.g Gal) or the acceptor (GlcNac) molecules to galac‐
tosyltransferases.  E.  g.  a  modified  GlcNac  acceptor,  called  compound 612,  was  recently
discovered  showing  differential  affinities  for  β4Gal-T1  and  β4Gal-T5,  two  galactosyl
transferases with similar acceptor specificities [102].  Also,  in contrast to other β4galacto‐
syltransferases,  β4Gal-T7  has  the  ability  to  bind,  but  not  actively  transfer  Mannose  or
GalNAc to an acceptor substrate, implying that these donors can be used as potential in‐
hibitors to GAG synthesis [103]
11.3. Lectins
During recent years, several laboratories, using specific cell lines that either over express
or lack different glycosyltransferases in combination with high density lectin microarrays.
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In order to entangle the mechanism by which the cellular glycome can influence stem cell
pluripotency and differentiation. Lectins are proteins that bind to particular carbohydrate
epitopes in a similar manner as an antibody. Glycans are located at the cell surface where
many  signal  transduction  pathways,  cell-cell  interaction  and  cell-to  cell  recognition  are
constantly active. Interactions between glycans and endogenous lectins may influence self
renewal,  maintenance  of  pluripotency  and  differentiaon  of  iPS/ESC.  Such  an  approach
has already been tested in which synthetic substrates, mimicking endogenous lectins, can
facilitate the formation of induced pluripotent cell( iPSC) and help sustain long term cul‐
ture of human ESCs [104]
12. Conclusion and perspectives
It is clear that both N-linked and O-linked glycans are implicated in many intricate and com‐
plex processes during development, differentiation and in many diseases. For many years
glycosyltransferases were thought of as just redundant enzymes acting solely in the ER and
Golgie, creating oligosaccharide structure mostly important for transport and solubility of
secreted proteins. However, in the last decades, the functions of glycosyl transferases have
been expanded to involve receptor oligomerization, antigen presentation, endocytosis, li‐
gand-receptor binding, and even signal transduction. These observations have attracted at‐
tention in the stem cell biology field. Several markers for pluripotency, such as Lewis X
antigen, e.g. SSEA-1, -3 and -4, and the keratin sulphate related markers, TRA-1-60 and
TRA-1-80, are all dependent on functional galactosylation for their synthesis and functional‐
ity. The levels and modifications of these embryonic derived antigens are changing upon
differentiation. These markers have mainly been used, and are still used, as markers for iso‐
lation and propagation of different stem cell populations. With recent technological advan‐
ces and the development of more efficient lectin microarrays and HPLC systems, more and
more details of the functional and structural requirements of early epitopes during stem cell
self renewal and differentiation, are emerging. These techniques, combined with specific
knock- down models and ectopical expression of individual galactosyltransferases, would
eventually reveal the molecular mechanisms by which glycans influence stem cell and can‐
cer progression. The complex interplay between members of the galactosyltransferase fami‐
ly, does not only affect the core structures of glycans but are also extensively involved in the
synthesis of other bioactive compounds, such as glycolipids and the Lexis X antigens that
affect a variety of biological systems spanning from cell migration to signal transduction.
The presence of the long form of β4Gal-T1 at the cell surface raises many interesting ques‐
tions on how this receptor, or maybe other glycosyltranferases as well, can influence so
many different signal transduction pathways in the regulation of cell cycle, cell death, prolif‐
eration and differentiation. Apart from being located to the Golgi complex, where it is re‐
sponsible for creating complex oligosaccharide structures on proteoglycans and glycolipid,
the cell surface β4Gal-Ts also affect intracellular signal transduction pathways. As seen in
Figure 6, cell surface β4GalTs can indirectly affect many cell specific functions because of its
involvement in the synthesis of glycolipids, embryoglycans and many embryonal epitopes,
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such Lewis X antigens. These complexes will either stabilize growth factor or cytokine-re‐
ceptor complexes or, after shedded into the extracellular matrix during differentiation, in‐
hibit receptor function. A change in galactosyltransferase activity could therefore indirectly
affect the stem cell nitch by hinder effective glycolipid, proteoglycan/GAG synthesis and
signal transduction through tyrosin kinase (TK) receptors. Secondly, apart from binding to
the extracellular matrix, such as laminin, the cell surface β4Gal-T1 could also act directly as
a lectin-like molecule that bind to tyrosine receptors (EGF, FGF or Notch), either on the
same cells, or on adjacent cells, as long as a terminal GlcNAc are presented. This could ei‐
Figure 6. Schematic view of cell surface β4GalTs potential functions. Cell surface as well as Golgi bound long β34Gal‐
actosyltransferase (GalTs) can influence stem cell homeostatis. TK; Tyrosin kinase. AC; actin, GC; Golgi complex, GL;Gly‐
colipid, PM; Plasma membrane, Ptyr; Tyrosine phosphorylation, PG; Proteoglycan, S04; sulphate, Neu;Neuramic acid,
Gal;Galactose, Glc;Glucose, Man;Mannose, GalNAc; N-Acetylgalactosamine, GalNAc; N-Acetylgalactoseamine, Fuc;Fu‐
cose.
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ther create a block or enhancement of the TK receptor- ligand complexes, or even hinder di‐
merization and activation of the receptors. Furthermore, the β4GalT-receptor binding could
lead to aggregation of cell surface β4Gal-T1, increasing its association to actin, and subse‐
quently lead to increase in intracellular signal transduction through FAK, SSeCKS and other
signalling molecules. In this scenario, it is plausible that β4GalTs, control a myriad regulato‐
ry feedback loops. It is clear that so much more of the biological function of GalTs has to be
understood in order to unravel attractive and potential therapies for cancer and in regenera‐
tive medicine.
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